CV Drugs - Antiplatelet & Anticoagulants Flashcards
formation of platelet plug
- platelet adhesion
- platelet activation
- platelet aggregation
- platelet plug formation
pampalabnaw ng dugo
CAMP (degraded by PDE)
activates platelet
thromboxane A2
P2Y receptor (ADP)
aspirin
irreversible cox inhibitor
inhibits conversoin to Txa2
antiplatelet
trifusal
irreversible cox inhibitor
inhibits conversoin to Txa2
antiplatelet
cilostazol
pde (-)
increases CAMP
antiplatelet
dipyridamole
pde (-)
increases CAMP
antiplatelet
clopidogrel
P2Y antagonist
antiplatelet
ticlopidine
P2Y antagonist
antiplatelet
regulates platelet adhesion and aggregation
glycoprotein (GP) IIb & IIIa
antiplatelet
eptifibatide
glycoprotein (GP) IIb & IIIa antagonist
antiplatelet
tirofiban
glycoprotein (GP) IIb & IIIa antagonist
antiplatelet
monitoring: heparin
activated partial thromboplastin time (intrinsic) - aPTT
monitoring: warfarin
prothrombin time/ international normal ratio (PT/INR)
common pathway in coagulation cascade
Xa
stimulates VII production
TF
tissue factor/ 3
dabigatran
direct thrombin inhibitor
argatroban
direct thrombin inhibitor
lepirudin
direct thrombin inhibitor
heparin
enoxaparin
unfractioned heparin (UFH)
LMWH
indirect thrombin inhibitor
fondaparinux
indirect thrombin inhibitor
warfarin
vit k epoxide reductase inhibitor
vit k dependent factors:
10,9,7,2
rivaroxaban
direct Xa inhibitor
aka novel oral anticoagulants (NOAC)
apixaban
direct Xa inhibitor
aka novel oral anticoagulants (NOAC)
destroys fibrin
plasmin
inactive: plasminogen
clot
fibrin
inactive: fibrinogen
streptokinase
fibrinolytic
activated tissue plasminogen activator (t-PA)
urokinase
fibrinolytic
activated tissue plasminogen activator (t-PA)
reteplase
analogue of alteplase
fibrinolytic
activated tissue plasminogen activator (t-PA)
alteplase
fibrinolytic
activated tissue plasminogen activator (t-PA)
tenecteplase
fibrinolytic
activated tissue plasminogen activator (t-PA)
uses of fibrinolytics
STEMI (when cant cardiac perfusion)
ischemic stroke